Lupin Receives USFDA Nod for Nasal Spray
Lupin, a Mumbai-based pharmaceutical company, received USFDA approval for Cyanocobalamin Nasal Spray, a generic version of Nascobal Nasal Spray by Par Pharmaceutical. This medication helps patients with pernicious anemia maintain normal vitamin B12 levels.
Cyanocobalamin Nasal Spray contains 500 mcg of cyanocobalamin per dose and offers an alternative option for patients requiring vitamin B12 supplementation. The generic version aims to make the medication more accessible and affordable for patients in need. According to IQVIA MAT March 2023 data, Cyanocobalamin Nasal Spray has estimated annual sales of $69 million in the United States, reflecting its popularity and demand.
Lupin is a leading global pharmaceutical company with a strong presence in diverse markets worldwide. With a focus on the generic equivalents of established medications, Lupin has been expanding its portfolio, solidifying its position in the industry. The recent USFDA approval for Cyanocobalamin Nasal Spray strengthens Lupin's market presence and underscores its dedication to delivering high-quality generic medications.
Share Market Today
| Indices Name | Price | Price Change (% change) |
|---|---|---|
| S&P ASX 200 | 7025.40 | -2.4 (-0.03%) |
| CAC 40 | 7089.83 | 18.04 (0.26%) |
| DAX | 15229.37 | 11.92 (0.08%) |
| Dow Jones | 33550.27 | -68.61 (-0.2%) |
| FTSE 100 | 7567.68 | -25.54 (-0.34%) |
| Hang Seng | 17364.31 | -218.54 (-1.24%) |
| US Tech 100 | 13097.85 | 29.24 (0.22%) |
| Nikkei 225 | 31872.52 | -499.38 (-1.54%) |
| S&P 500 | 4274.51 | 0.98 (0.02%) |
| Gift Nifty | 19641.00 | -77 (-0.39%) |
| Shanghai Composite | 3110.48 | 3.16 (0.1%) |
| Taiwan Weighted | 16353.74 | 43.38 (0.27%) |
| US 30 | 33579.10 | -5.8 (-0.02%) |
Start Investing in 5 mins*
Rs. 20 Flat Per Order | 0% Brokerage
Fill in your details below: